Grant Life Sciences Inc. (OTC BB: GLIF) announced today that it has received a purchase order from an arm of the Indian government for two million of its point-of-care (POC), ‘rapid’ malaria tests, to be delivered by year-end. Grant intends to ship approximately 25 percent of the total order immediately. These malaria tests are part of the ‘AccuDx’ rapid-test product line to which Grant holds exclusive rights from AccuDx Corp.--a biotechnology company founded by Ravi Pottathil, Ph.D., one of the world’s leading authorities in the field of HIV/AIDS diagnostics and therapeutics. The AccuDx portfolio includes additional rapid tests for HIV-1, HIV-2, for example, and Dengue Fever
